# To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

> **NCT00191191** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 226 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed 500 mg/m2
- **DRUG:** Pemetrexed 1000 mg/m2

## Key facts

- **NCT ID:** NCT00191191
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2009-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191191, "To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00191191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*